Galapagos achieves EUR 3.4 million milestone payment from Janssen Pharmaceutica NV
29-Jan-2008
On 24 October 2007, Galapagos announced an alliance agreement with Janssen providing it with option rights to acquire worldwide, commercial licenses to novel small-molecules from up to 12 of Galapagos' internal programs involving rheumatoid arthritis (RA) therapeutic targets. The milestone announced today was due to the achievement of a milestone with respect to the GT146 program.
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.